IL4 and COVID-19: For instance, monoclonal antibodies against IL-4 (dupilumab) have been used in patients with atopic dermatitis and COVID-19 without increasing the risk of severe complications and even apparently reducing respiratory symptoms (Caroppo and others 2020; Carugno and others 2020; Ferrucci and others 2020; Ungar and others 2022).